Zhou et al. (2021) found lower sclerostin levels in 168 patients affected by non-alcoholic fatty liver disease [16]—a major feature of metabolic syndrome—in accordance with previous observations reported by Polyzos et al. (2016) in 27 patients with biopsy-proven steatosis or steatohepatitis [17]. This evidence concerns the gene SOST and metabolic syndrome.